Literature DB >> 16175378

Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year-old girl.

Michael J Potter1, Shelagh M Szabo, Terrence Ho.   

Abstract

BACKGROUND: Combination photodynamic therapy with verteporfin (PDT) and intravitreal triamcinolone acetonide (IVT) is currently being investigated as a treatment for choroidal neovascularization (CNV) due to age-related macular degeneration. However, PDT with triamcinolone has never previously been described in the treatment of CNV secondary to pathologic myopia, or in a young person. We describe the case of a young girl treated with combination PDT and IVT for a myopic subfoveal CNV membrane.
METHODS: This study was an interventional case report. The medical chart of a 13-year-old child treated with combination PDT with IVT was reviewed for changes in visual acuity on the ETDRS chart, CNV leakage on fluorescein angiography, and adverse events reported.
RESULTS: ETDRS visual acuity improved from 20/80-2 to 20/25 in the right eye over 7 months following two treatments of a myopic CNV lesion with combination PDT and IVT. Following treatment, an inactive scar with no further leakage was visible on fluorescein angiography. An increase in intraocular pressure was associated with the second IVT treatment, and successfully treated with topical therapy.
CONCLUSIONS: Combination PDT with IVT may be considered under appropriate circumstances to treat children with CNV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16175378     DOI: 10.1007/s00417-005-0115-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  8 in total

1.  Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.

Authors:  Donald J D'Amico; Morton F Goldberg; Henry Hudson; Janice A Jerdan; Scott Krueger; Susan Luna; Stella M Robertson; Stephen Russell; Lawrence Singerman; Jason S Slakter; E Kenneth Sullivan; Lawrence Yannuzzi; Patricia Zilliox
Journal:  Retina       Date:  2003-02       Impact factor: 4.256

2.  Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration.

Authors:  E Rechtman; R P Danis; L M Pratt; A Harris
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

3.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

4.  Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups.

Authors:  Takeshi Yoshida; Kyoko Ohno-Matsui; Yoshiteru Ohtake; Takayuki Takashima; Soh Futagami; Takayuki Baba; Kenjiro Yasuzumi; Takashi Tokoro; Manabu Mochizuki
Journal:  Ophthalmology       Date:  2002-04       Impact factor: 12.079

5.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02

6.  Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment.

Authors:  Ruth Axer-Siegel; Rita Ehrlich; Dov Weinberger; Irit Rosenblatt; Ludmila Shani; Yuval Yassur; Ethan Priel; Michal Kramer
Journal:  Am J Ophthalmol       Date:  2004-10       Impact factor: 5.258

7.  Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.

Authors:  Richard F Spaide; John Sorenson; Leandro Maranan
Journal:  Ophthalmology       Date:  2003-08       Impact factor: 12.079

8.  Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in children.

Authors:  Karin F Mimouni; Susan B Bressler; Neil M Bressler
Journal:  Am J Ophthalmol       Date:  2003-06       Impact factor: 5.258

  8 in total
  8 in total

1.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Javier A Montero; Jose M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

2.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Amy L Wong; David T L Liu; Dennis S C Lam
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

3.  Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.

Authors:  Izumi Yamamoto; Adam H Rogers; Elias Reichel; Paul A Yates; Jay S Duker
Journal:  Br J Ophthalmol       Date:  2006-07-26       Impact factor: 4.638

4.  Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?

Authors:  Bogomil Voykov; Faik Gelisken; Werner Inhoffen; Michael Voelker; Karl Ulrich Bartz-Schmidt; Focke Ziemssen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-01-29       Impact factor: 3.117

5.  Choroidal neovascularization in 36 eyes of children and adolescents.

Authors:  P Rishi; A Gupta; E Rishi; B J Shah
Journal:  Eye (Lond)       Date:  2013-07-26       Impact factor: 3.775

6.  Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: A one-year follow-up controlled study.

Authors:  Sandro Saviano; Rita Piermarocchi; Pia E Leon; Alessandro Mangogna; Andrea Zanei; Fabiano Cavarzeran Sc; Daniele Tognetto
Journal:  Int J Ophthalmol       Date:  2014-04-18       Impact factor: 1.779

7.  [Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia].

Authors:  S Dithmar; K B Schaal; A E Höh; S Schmidt; F Schütt
Journal:  Ophthalmologe       Date:  2009-06       Impact factor: 1.059

8.  Choroidal neovascularization in 111 eyes of children and adolescents.

Authors:  Pukhraj Rishi; Rekha Priya Kalluri Bharat; Ekta Rishi; Muna Bhende; Jyotirmay Biswas; Arshee Ahmed; Sridharan Sudharshan
Journal:  Int Ophthalmol       Date:  2021-08-23       Impact factor: 2.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.